Patent term adjustment debate resurfaces, raising questions on predictability and innovation in healthcare
The discussion on reintroducing a patent term adjustment (PTA) mechanism has resurfaced in Brazil’s healthcare sector, bringing renewed attention to regulatory predictability and innovation incentives.
While part of the industry views the mechanism as a way to strengthen legal certainty and attract investment, stakeholders linked to generics, biosimilars, and public health argue that the current framework already provides sufficient protection without extending patent terms.
Regulatory background
Since 2021, Brazil has not maintained a mechanism to compensate for delays in patent examination. This followed a Supreme Court ruling that invalidated provisions guaranteeing a minimum patent term in such cases.
Legislative proposals are now under discussion to reintroduce a structured adjustment model, including:
- Proportional extensions based on administrative delays
- A maximum adjustment period of up to five years
- Defined deadlines for requesting adjustments after grant
These proposals aim to align Brazil with international practices.
Predictability and innovation impact
Predictability in patent systems is a key factor influencing R&D investment decisions.
Extended examination timelines can:
- Reduce legal certainty over intellectual property rights
- Increase transaction and licensing costs
- Delay market entry of new technologies
Compared to leading economies such as China, Brazil’s patent activity remains significantly lower, reinforcing the debate on how to strengthen its innovation ecosystem.
Patent Term Adjustment (PTA)
PTA is a mechanism designed to compensate patent holders for undue administrative delays in the examination process.
Its main features include:
- Case-specific application rather than automatic extension
- Eligibility tied to unjustified delays by the patent office
- Objective of restoring effective exclusivity time
The mechanism is widely used internationally to balance protection and regulatory efficiency.
Trade-offs: access vs. innovation
Reintroducing PTA involves a strategic policy choice:
- Access-oriented approach: prioritizing affordability through generics and biosimilars
- Innovation-driven approach: encouraging investment and technology inflow
Balancing these priorities is critical in a sector characterized by high development costs and strong reliance on intellectual property protection.
Next steps
The debate continues across legislative and industry forums. Any future adoption of a PTA mechanism is expected to influence:
- Investment strategies in Brazil
- Competitive dynamics in the pharmaceutical sector
- Access to new treatments and technologies










